FDA Fast-Tracks Review of Promising Alzheimer's Drug

Thursday, 18 Jul 2013 07:39 AM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
Canadian biopharmaceutical company Transition Therapeutics said the U.S. Food and Drug Administration granted a fast-track status to its Alzheimer's drug, sending its U.S.-listed shares up 33 percent in post-market trading.

A fast track designation by the FDA expedites regulatory review of drugs that aim to treat serious diseases and fill unmet medical needs.
 
The drug, ELND005, currently being tested in a mid-stage trial, treats neuropsychiatric symptoms such as agitation or aggression in Alzheimer's disease.
 
Transition Therapeutics said the drug appeared to decrease the emergence and severity of specific neuropsychiatric symptoms in a previous mid-stage study.
 
About 90 percent of Alzheimer's patients develop neuropsychiatric symptoms and up to 60 percent develop agitation over the course of their disease, the company said.
 
Ireland-based Elan Corp Plc is Transition's marketing and development partner.
Transition Therapeutics' Toronto-listed shares closed at C$3.15 (U.S. $3.02) on Wednesday.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Diagnose Your Kid's Ear Infection With Your iPhone

Friday, 19 Dec 2014 16:15 PM

Diagnosing your kid's ear infections might soon be as simple as taking a video on your smartphone. . . .

Revlon Removing Some Dangerous Chemicals From Cosmetics

Friday, 19 Dec 2014 16:11 PM

Revlon announced that it will no longer use two chemical ingredients in its products, responding to a consumer petition  . . .

New Ovarian Cancer Drug Gets FDA OK

Friday, 19 Dec 2014 15:48 PM

The U.S. Food and Drug Administration has approved a new drug to treat advanced ovarian cancer, along with a test to ide . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved